Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India
Year: 2026
Type: article
Abstract: Objectives: Prostate cancer is the second most prevalent cancer among men and increasingly affects younger individuals. These younger patients display distinct clinical and pathological profiles, with unclear prognostic outcomes. This study retrospectively analyses prostate cancer cases in men aged ≤55 years treated at Tata Memorial Hospital to understand the disease's characteristics and outcomes in this age group. Material and Methods: From 2012–2021, electronic medical records identified patients aged ≤55 years diagnosed with metastatic prostate cancer. Clinical and treatment data were extracted for analysis. Results: The cohort comprised 150 patients (median age: 52 years). Most cases (95%) were adenocarcinoma, while 4% had neuroendocrine differentiation, and 1% presented pure small cell carcinoma. High-grade disease (Gleason 4–5) was common (87%), with 91% having prostate-specific antigen (PSA) levels >20 ng/mL. Bone metastases were predominant (91%), and 73% had high-volume disease. Treatment involved surgical castration (62%) or medical castration (38%). Initial therapies included docetaxel (52%), abiraterone (11%), or androgen deprivation therapy (ADT) alone (29%). ADT alone was more common before 2019, when combination therapies were less utilised. With a median follow-up of 61.4 months, the median overall survival (mOS) was 47.1 months, while survival post-castration resistance was 20.1 months. The mOS for ADT compared to ADT plus docetaxel or abiraterone was 44.8 vs. 59.2 months ( p = 0.062) in patients with low volume disease, and 37.7 versus 49.6 months ( p = 0.563) in patients with high volume disease. This lack of statistical significance may be attributed to the high proportion (28.4%) of high-volume disease patients who received ADT alone. Poor prognostic factors included neuroendocrine differentiation, Gleason 5, high disease volume, and visceral metastases. Conclusion: Younger prostate cancer patients demonstrate more aggressive disease and worse outcomes compared to older cohorts. Prospective randomised trials are crucial to optimising management for this distinct population.
Source: South Asian Journal of Cancer
DOI: 10.25259/sajc_9_2025
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7237347498
